Eloisi Caldas-Lopes

Cornell University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index1.5kcitations20works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Heat shock proteins research(12), Computational Drug Discovery Methods(3), Endoplasmic Reticulum Stress and Disease(3), ATP Synthase and ATPases Research(3), Protein Structure and Dynamics(2)

Publications20 total

Qpctl Inhibition, By Targeting the Inflammatory Tumor Microenvironment, Constitutes a Novel Therapeutic Approach for Diffuse Large B-Cell Lymphoma
Blood·2023· 3 cited
Paradigms for Precision Medicine in Epichaperome Cancer Therapy
Cancer Cell·2019· 56 citedOpen Access
Targeting Aurora-kinase B with the novel Aurora Kinase B inhibitor MK7 in multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2019· 1 cited
Approaches to Targeting Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy·2019· 5 cited
A novel tetrazole analogue of resveratrol is a potent anticancer agent
Bioorganic & Medicinal Chemistry Letters·2018· 38 cited
The epichaperome is an integrated chaperome network that facilitates tumour survival
Nature·2016· 294 citedOpen Access
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species
Cell Reports·2015· 62 citedOpen Access
Abstract 5444: Development of a noninvasive assay to determine drug concentration in tumor during hsp90 inhibitor therapy
Cancer Research·2015
Abstract 3029: Biochemical evidence towards the existence of an oncogenic Hsp90 complex
Cancer Research·2012· 10 cited
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Nature Chemical Biology·2011· 258 citedOpen Access
Abstract 2579: YK5, a small molecule inhibitor of Hsp70 and Hsc70, reveals a multifaceted role for the Hsp70 chaperones in regulating oncogenic and non-oncogenic addiction of tumors
Cancer Research·2011
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy
Journal of Clinical Investigation·2010· 120 citedOpen Access
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Journal of Clinical Investigation·2010· 178 citedOpen Access
Abstract 5463: YK5, a novel dual Hsc70 and Hsp70 inhibitor, is selective for tumor Hsp70 and has potent but selective activity in cancer cells
Cancer Research·2010
Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using 89Zr-DFO-Trastuzumab
PLoS ONE·2010· 129 citedOpen Access
Abstract A226: ImmunoPET with 89Zr-DFO-trastuzumab: Monitoring the pharmacodynamic effects on HER2/<i>neu</i> expression by Hsp90 inhibition <i>in vivo</i>
Molecular Cancer Therapeutics·2009
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
Proceedings of the National Academy of Sciences·2009· 309 citedOpen Access
Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma #
Hepatology·2009· 73 citedOpen Access
Hsp90 als potentielle neue Zielstruktur zur Behandlung des hepatozellulären Karzinoms (HCC)
Zeitschrift für Gastroenterologie·2009
Synergy of the Purine-Scaffold HSP90 Inhibitor, PU-H71, with Doxorubicin in Non-Hodgkin’s Lymphoma Cell Lines.
Blood·2007· 2 cited

Frequent Co-authors

Gabriela Chiosis(16), Tony Taldone(12), Anna Rodina(10), Mónica L. Guzmán(9), Ari Melnick(8), Leandro Cerchietti(7), Jason S. Lewis(7), Nagavarakishore Pillarsetty(5), Hediye Erdjument‐Bromage(5), Ross L. Levine(5), Steven M. Larson(5), James H. Ahn(4), Hongliang Zong(4), Mary L. Alpaugh(4), Danuta Zatorska(4), Thomas W. Ku(4), Kamalika Moulick(3), Alexander Gozman(3), Steven S. Gross(3), Pengrong Yan(3)